8th HTAi annual meeting

Gostaria de registrar aqui a participação no 8o Encontro Anual do HTAi realizado no final de junho aqui no Rio de Janeiro. O congresso teve participação de vários players da área de saúde (Setor Privado, Público, Consultorias, Indústrias Farmacêuticas) e foi uma ótima troca de experiências. Foram apresentadas palestras e discussões riquíssimas além de posteres  dentre os quais tive a oportunidade de participar, todos pela empresa BMS:

DIAPS79: COST-UTILITY ANALYSIS OF SAXAGLIPTIN VERSUS SULFONYLUREA AS AN ADD-ON THERAPY TO METFORMIN IN TYPE 2 DIABETES PATIENTS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

DIAPS79: A COST-UTILITY ANALYSIS OF SAXAGLIPTIN AS AN ADD-ON THERAPY TO METFORMIN IN TYPE 2 DIABETES PATIENTS FROM THE BRAZILIAN PRIVATE HEALTH SYSTEM 

DIAPS 79 STUDY: BUDGET IMPACT ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF DIABETES MELLITUS TYPE 2 (T2DM) UNDER THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM 

DIAPS 79 STUDY: TREATMENT PATTERNS AND ACHIEVEMENT OF THERAPEUTIC GOALS IN A COHORT OF TYPE 2 DIABETES MELLITUS PATIENTS TREATED IN THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM

KIT73 STUDY: RELATIONSHIP BETWEEN COSTS OF CARE AND 12-MONTH GLOMERULAR FILTRATION RATES IN POST-KIDNEY TRANSPLANT PATIENTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM (SUS) 

KIT73 STUDY: DOES TYPE OF DONOR INFLUENCE LONG-TERM COSTS OF CARE? RESULTS FROM POST-KIDNEY TRANSPLANT PATIENTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM (SUS) DATASUS 

KIT73 STUDY: IMMUNOSUPPRESSANT THERAPY PATTERNS AND ITS COSTS IN THE NATIONAL RENAL TRANSPLANT PROGRAM IN BRAZIL 

KIT73 STUDY: POST-RENAL TRANSPLANT RE-HOSPITALIZATIONS IN THE BRAZILIAN PUBLIC HEALTH SYSTEM: CAUSES, RESOURCES USE AND COSTS BASED ON DATASUS DATA IMPACT OF NON-ADHERENCE TO IMATINIB ON PROGRESSION-FREE SURVIVAL AS 1ST TREATMENT FOR CHRONIC MYELOID LEUKEMIA IN BRAZIL: TWO YEARS FOLLOW UP 

MELODY BRASIL: TREATMENT PATTERNS AND ASSOCIATED COSTS OF METASTATIC MELANOMA PATIENTS IN THE BRAZILIAN PUBLIC HEALTH SYSTEM SETTINGS (SUS) 

MELODY BRAZIL: CHEMOTHERAPY CHOICES FOR PATIENTS WITH METASTATIC MELANOMA IN THE PUBLIC HEALTH CARE SYSTEM (SUS) 

CARDIOMETABOLIC DISEASE RISK AMONG SCHIZOPHRENIA PATIENTS TREATED WITH ARIPIPRAZOLE VERSUS OLANZAPINE IN BRAZIL: A COST-CONSEQUENCE ANALYSIS